Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty

• Status: Completed
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This prospective study compares an oral direct factor Xa inhibitor with LMWH for thromboprophylaxis in the patients undergoing THA.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Samsung Medical Center
• Treatments: Enoxaparin; Rivaroxaban

Criteria

Inclusion Criteria:

• Male or female without childbearing potential aged ≥20 years who were scheduled for elective primary THA

Exclusion Criteria:

• recent history of active bleeding or VTE

• known genetic disorder associated with bleeding tendency or any condition related with an increased risk of bleeding

• persistent blood pressure of ≥160mmHg systolic and/or ≥100 mmHg diastolic at baseline

• myocardial infarction or cerebrovascular accident within three months of the scheduled surgery

• major surgery in the prior three months

• renal insufficiency with a creatinine clearance <60mL/min , hepatic failure combined with coagulopathy, or thrombocytopenia (platelets < 100,000/mm³), or planned indwelling epidural catheter for > 6 hours after the end of surgery